JUBLPHARMA - Technical Analysis with Chart Patterns & Indicators
Back to ListTechnical Rating: 3.2
| Stock Code | JUBLPHARMA | Market Cap | 14,761 Cr. | Current Price | 927 ₹ | High / Low | 1,250 ₹ |
| Book Value | 141 ₹ | Dividend Yield | 0.54 % | ROCE | 2.91 % | ROE | 1.04 % |
| Face Value | 1.00 ₹ | DMA 50 | 904 ₹ | DMA 200 | 981 ₹ | Chg in FII Hold | -0.06 % |
| Chg in DII Hold | 0.40 % | PAT Qtr | 6.60 Cr. | PAT Prev Qtr | -48.0 Cr. | RSI | 59.3 |
| MACD | 19.7 | Volume | 66,902 | Avg Vol 1Wk | 1,30,628 | Low price | 784 ₹ |
| High price | 1,250 ₹ | Debt to equity | 0.02 | 52w Index | 30.6 % | Qtr Profit Var | 154 % |
| EPS | 1.23 ₹ | Industry PE | 30.1 |
📊 Chart & Indicators
- Current price (₹927) is above DMA 50 (₹904) but below DMA 200 (₹981), showing short-term strength but medium-term weakness.
- RSI at 59.3 indicates healthy momentum, close to overbought territory.
- MACD at 19.7 shows bullish crossover, supporting upward bias.
- Bollinger Bands: price near upper band, suggesting strong momentum but risk of pullback.
- Volume (66.9K) below average (1.30 Lakh), showing weak participation.
🎯 Entry & Exit Zones
- **Entry Zone:** ₹910 – ₹930 (near DMA 50 support).
- **Exit Zone:** ₹970 – ₹1,000 (resistance zone).
- **Stop-Loss:** Below ₹890 (support breakdown risk).
📈 Trend Status
- The stock is **consolidating with mild bullish bias**.
- Sustained breakout above ₹981 (DMA 200) required for medium-term reversal.
- Weak volume suggests cautious accumulation.
✅ Positive
- Price trading above DMA 50.
- EPS at ₹1.23 with positive PAT recovery.
- Debt-to-equity ratio at 0.02, showing very low leverage.
- DII holdings increased (+0.40%).
- Quarterly PAT recovery from loss (-₹48 Cr. → ₹6.6 Cr.).
⚠️ Limitation
- ROCE (2.91%) and ROE (1.04%) remain very weak.
- No P/E or PEG ratio provided, limiting valuation clarity.
- Dividend yield modest at 0.54%.
- Volume below average, limiting conviction.
📉 Company Negative News
- Weak profitability metrics with low ROE and ROCE.
- FII holdings decreased (-0.06%).
- Earnings volatility remains a concern despite recovery.
📈 Company Positive News
- PAT recovery from losses shows operational improvement.
- Domestic institutional inflows provide support.
- Technical indicators (MACD, RSI) showing bullish bias.
🏭 Industry
- Industry PE at 30.1 vs JUBLPHARMA’s undefined P/E, making valuation comparison difficult.
- Pharma sector supported by demand growth but facing margin pressures from R&D and regulatory costs.
🔎 Conclusion
JUBLPHARMA is consolidating with mild bullish signals from MACD and RSI, supported by PAT recovery and low leverage. Fundamentals remain weak with poor ROE/ROCE and limited valuation clarity. Entry near ₹910–₹930 is favorable for tactical trades, with exits around ₹970–₹1,000. Sustained breakout above DMA 200 is required for medium-term bullish reversal.
Would you like me to extend this into a long-term investment overlay for JUBLPHARMA, highlighting compounding potential and sector benchmarking against peers like Sun Pharma and Dr. Reddy’s?